Search results
Results from the WOW.Com Content Network
Editas Medicine was originally founded with the name "Gengine, Inc." in September 2013 by Feng Zhang of the Broad Institute, Jennifer Doudna of the University of California, Berkeley, [7] and George Church, David Liu, and J. Keith Joung of Harvard University, with funding from Third Rock Ventures, Polaris Partners and Flagship Ventures; the name was changed to the current "Editas Medicine" two ...
Editas (EDIT) focuses on the development of its lead candidate, EDIT-101, for treating LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a woe.
After another solid quarter of progress, the genome-editing company looks forward to a phase 1/2 study for its revolutionary CRISPR medicine. Editas Medicine Prepares to Make History With EDIT-101 ...
Editas (EDIT) pauses enrollment in the phase I/II BRILLIANCE study evaluating EDIT-101 for treating blindness due to Leber congenital amaurosis 10. Stock falls.
CAMBRIDGE, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced the sale of certain future license fees and other payments owed to Editas Medicine under its Cas9 license agreement with Vertex Pharmaceuticals to a wholly-owned subsidiary of DRI Healthcare Trust (DRI) for an upfront cash payment of $57 million.
James C. “Jim” Mullen (born ca. 1958) is an American business executive. He is the executive chairman at genome editing company Editas Medicine since 2018, where he also served as CEO between 2021 and 2022.
Feng Zhang (Chinese: 张锋; pinyin: Zhāng Fēng; born October 22, 1981) is a Chinese–American biochemist.Zhang currently holds the James and Patricia Poitras Professorship in Neuroscience at the McGovern Institute for Brain Research and in the departments of Brain and Cognitive Sciences and Biological Engineering at the Massachusetts Institute of Technology.
Editas (EDIT) doses the first patient pediatric patient in the BRILLIANCE study on EDIT-101 for treating Leber congenital amaurosis 10 (LCA10).